Shots:
- The P-IIb X-TOLE clinical trial evaluates the efficacy, safety, & tolerability of XEN1101 (25/20/10mg) vs PBO in 325 & 323 patients (in the safety & ITT population, respectively) with focal epilepsy
- The trial met its 1EPs i.e., patients achieved a median reduction in monthly focal seizure frequency from baseline (52.8%/46.4%/33.2% vs 18.2%), and other measures included a ≥50% reduction in monthly focal seizure frequency from baseline (54.5%/43.1/28.3 vs 14.9). The therapy was generally well-tolerated
- The therapy leads to treatment discontinuation due to AEs (15.8%/13.7%/ 2.2% vs 3.5), higher incidence of TEAEs (85.1%/ 68.6%/ 67.4% vs 62.3)
Click here to read full press release/ article | Ref: Globe Newswire | Image: BioSpace
The post Xenon’s XEN1101 Meets its Primary Efficacy Endpoint in P-IIb X-TOLE Clinical Trial for the Treatment of Focal Epilepsy first appeared on PharmaShots.
